Hepatotoxicity of vascular endothelial growth factor receptor tyrosine kinase inhibitors: clinical practice and evidence

dc.contributor.authorÇetin, Bülent
dc.contributor.authorBilgetekin, İrem
dc.contributor.authorCengiz, Mustafa
dc.contributor.authorÖzet, Ahmet
dc.date.accessioned2020-12-19T20:17:22Z
dc.date.available2020-12-19T20:17:22Z
dc.date.issued2017
dc.departmentRTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractVascular endothelial growth factor (VEGF) plays an important role in the growth of tumor cells, and in their invasion, metastasis, and angiogenesis. Kinase inhibitors (which are taken orally, work intracellularly, and can inhibit one or more kinases) constitute a rapidly growing and important part of the oncology armamentarium. Although these treatments have dramatically changed the natural course of many cancers, they may result in hepatic complications, which can be manifested during the course of therapy. More effort must be devoted to manipulating the dose and schedule of kinase inhibitor therapy to maximize efficacy and minimize toxicity. When these agents are used, judicious management of adverse effects should be carried out in the early phases of treatment. This article focuses on the hepatocellular toxic effects that may be associated with these new targeted cancer therapies and provides a broad overview of this emerging field. © 2017, Springer International Publishing AG Switzerland.
dc.identifier.citationÇetin, B., Bilgetekin, İ., Cengiz, M. & Özet, A. (2017). Hepatotoxicity of vascular endothelial growth factor receptor tyrosine kinase inhibitors: clinical practice and evidence. Drugs and Therapy Perspectives, 33(8), 395-402. https://doi.org/10.1007/s40267-017-0416-8
dc.identifier.doi10.1007/s40267-017-0416-8
dc.identifier.endpage402
dc.identifier.issn1172-0360
dc.identifier.issue8
dc.identifier.scopus2-s2.0-85024117670
dc.identifier.scopusqualityQ3
dc.identifier.startpage395
dc.identifier.urihttps://doi.org/10.1007/s40267-017-0416-8
dc.identifier.urihttps://hdl.handle.net/11436/4377
dc.identifier.volume33
dc.indekslendigikaynakScopus
dc.institutionauthorÇetin, Bülent
dc.language.isoen
dc.publisherSpringer International Publishing
dc.relation.ispartofDrugs and Therapy Perspectives
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleHepatotoxicity of vascular endothelial growth factor receptor tyrosine kinase inhibitors: clinical practice and evidence
dc.typeReview Article

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
çetin-2017.pdf
Boyut:
503.74 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text